SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
1. Alto is facing a securities class action lawsuit. 2. Claims allege misleading statements about ALTO-100's effectiveness. 3. Stock price fell 69.99% after failure to meet trial endpoints. 4. Jefferies downgraded Alto with a new price target of $17. 5. Investors have until September 19, 2025, to join the class action.